Company Information

  

Address: 8 CROSS STREET
#10-00 
City: SINGAPORE 
State:  
Zip Code: 048424 
Telephone: 617-206-4830 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a genetic medicines company with an innovative and proprietary synthetic chemistry drug development platform that we are using to design, develop and commercialize a broad pipeline of first-in-class or best-in-class nucleic acid therapeutic candidates for genetically defined diseases. Nucleic acid therapeutics are a growing and innovative class of drugs that have the potential to address diseases that have historically been difficult to treat with small molecule drugs or biologics. Oligonucleotides are comprised of a sequence of nucleotides that are linked together by a backbone of chemical bonds. We are initially developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics we are developing are stereopure.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2017-2.96NAN/E
12/2016-2.43NAN/E
03/2016-0.37NAN/E
12/2015-1.83NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.25Total Liab/Total Assets0.13
Net Inc/Total Assets-0.34Total Liab/Inv Cap0.14
Net Inc/Inv Cap-0.36Total Liab/Comm Equity0.10
Pretax Inc/Net Sales-36.89Interest Coverage RatioNA
Net Inc/Net Sales-37.31Curr Debt/Equity0.00
Cash Flow/Net Sales-21.46LTD/Equity0.00
SG&A/NetSales10.77Total Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables Turnover12.80Quick Ratio12.50
Inventory TurnoverNACurrent Ratio12.50
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.01Inv/Curr AssetsNA
Net Sales/PP&E0.17  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.68 0.68 0.68 0.39
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 6.67 5.85 5.19 3.94
Operating Income -25.09 -19.91 -18.50 -17.23
Interest Exp NA NA NA NA
Pretax Income -24.68 -19.69 -18.27 -17.15
Other Income 0.42 0.22 0.23 -0.04
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -24.69 -21.00 -18.45 -17.54

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 197.39 129.48 150.29 169.02
Receivables - Total 0.00 0.00 0.21 2.50
Inventories - Total NA NA NA NA
Total Current Assets 201.22 132.78 151.99 172.14
Net Property, Plant & Equipment 20.78 14.30 8.61 6.69
Total Assets 226.43 151.51 164.81 179.97
Liabilities        
Accounts Payable 12.57 11.19 9.39 8.66
Debt in Current Liabilities 0.28 0.18 0.06 0.06
Total Current Liabilities 15.56 14.07 12.16 11.43
Long-Term Debt 2.20 1.08 0.02 0.03
Total Liabilities 29.65 26.55 22.07 20.97
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 309.36 215.81 215.60 215.51
Retained Earnings -136.17 -111.47 -90.48 -72.02
Treasury Stock NA NA NA NA
Total Stockholders' Equity 188.91 117.09 134.86 151.13
Total Liabilities and Stockholders' Equity 218.56 143.63 156.94 172.10

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -20.09 -17.42 -13.29 -11.83
Net Cash Provided by Investing Activities -5.57 -3.64 -5.33 -1.28
Net Cash Provided by Financing Activities 93.54 0.19 0.02 0.18

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-3.32--
12/20140.00-5.23--
12/20150.15-19.20-1.83
12/20161.48-55.40-2.43
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/175919,31669.58




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.